Pharmacotherapy and blood pressure control in elderly hypertensives in a primary care setting in Bahrain
First Online: 25 July 2013 Received: 28 May 2003 Revised: 11 December 2003 Accepted: 11 December 2003 DOI:
Cite this article as: Jassim Al Khaja, K.A., Sequeira, R.P. & Damanhori, A.H.H. Aging Clin Exp Res (2004) 16: 319. doi:10.1007/BF03324558 Abstract Background and aims: Antihypertensive treatment in the elderly has important beneficial effects in terms of reduced cardiovascular morbidity and mortality. The aim of this study was to determine, in elderly hypertensives, the adherence of primary care physicians to World Health Organization/International Society of Hypertension (WHOASH) guidelines for the drug management of hypertension and extent of blood pressure (BP) control. Methods: A multicentric therapeutic audit of medical records of elderly hypertensives was performed in nine primary care health centers in the Kingdom of Bahrain. Results: In elderly hypertensives (≥60 years), the WHQ/ISH-1999 recommended BP targets of <140/<90 mmHg and BP<130/85 mmHg were achieved in 11.1% of elderly hypertensives and 4.1% of elderly diabetic hypertensives, respectively. Antihypertensive combination therapy was used in approximately half of the elderly. No significant difference in BP was found in elderly hypertensives treated either with monotherapy or combination therapy. As regards mono- and overall drug utilization, β-blockers were the most frequently prescribed drugs in hypertensives, and angiotensin-converting enzyme (ACE) inhibitors in diabetic hypertensives. Diuretics and calcium channel blockers, the preferred antihypertensives for the elderly, were less often prescribed, particularly in patients with isolated systolic hypertension. Conclusions: Approximately one out of 9 elderly hypertensives and one out of 24 diabetic hypertensives achieved optimal BP control. Although preference for antihypertensives was markedly influenced by comorbidity with diabetes, tailoring of drug therapy was suboptimal and did not adhere to the recommended guidelines in elderly hypertensives. Efforts to improve the drug management of hypertension at primary care level, particularly in the elderly, are required. Keywords Antihypertensive therapy BP control clinical guidelines diabetes elderly hypertensives isolated systolic hypertension
The abstract of this paper was presented at the 13th European Meeting on Hypertension, June 13–17, 2003, Milan, Italy.
National High Blood Pressure Education Program Working Group Report on Hypertension in the Elderly: National High Blood Pressure Education Program Working Group. Hypertension 1994; 23: 275–85.
Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risk. Arch Intern Med 1993; 153: 598–615.
Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997; 157: 2413–46.
World Health Organization/International Society of Hypertension (WHO/ISH). Guidelines for the management of hypertension. J Hypertens 1999; 17: 151–83.
Ramsay LE, Williams B, Johnston GD, et al. for the British Hypertension Society. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999; 13: 569–92.
McAlister FA, Levine M, Zarnke KB, et al. for the Canadian Hypertension Recommendations Working Group. The 2000 Canadian recommendations for the management of hypertension: Part 1- therapy. Can J Cardiol 2001; 17: 543–59.
2003 European Society of Hypertension — European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53.
Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289: 2560–72.
Fagan TC, Sowers JR. Type 2 diabetes mellitus: greater cardiovascular risks and greater benefits of therapy. Arch Intern Med 1999; 159: 1033–4.
Grossman E, Messerli FH, Goldbout U. High blood pressure and diabetes mellitus: are all antihypertensive drugs created equal? Arch Intern Med 2000; 160: 2447–52.
Epstein M, Sower JR. Diabetes mellitus and hypertension. Hypertension 1992; 19: 403–18.
Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996; 276: 1886–92.
Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effect of calcium channel blockage in older patients with diabetes and systolic hypertension: Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999; 340: 677–84.
Wang JG, Staessen JA, Gong L, Liu L, for the Systolic Hypertension in China (Syst-China) Collaborative Group. Chinese trial on isolated systolic hypertension in the elderly. Arch Intern Med 2000; 160: 211–20.
Al Khaja KAJ, Sequeira RP, Mathur VS. Rational pharmacotherapy of hypertension in the elderly: analysis of the choice and dosage of drugs. J Clin Pharm Ther 2001; 26: 33–42.
Al Khaja KAJ, Sequeira RP, Mathur VS, Damanhori AHH, Abdul Wahab AWM. Family physicians’ and general practitioners’ approach to drug management of diabetic hypertension in primary care. J Eval Clin Pract 2002; 8: 19–30.
Wang JG, Staessan JA. Benefits of antihypertensive drug treatment in elderly patients with isolated systolic hypertension. Neth J Med 2001; 58: 248–54.
Messerli FH, Grossman E, Goldbourt U. Are β-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 79: 1903–7.
Al Khaja KAJ, Sequeira RP, Abdul Wahab AWM, Mathur VS. Antihypertensive drug prescription trends at the primary health care centers in Bahrain. Pharmacoepid Drug Saf 2001; 10: 219–27.
Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American Settings: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 2002; 4: 393–405.
National High Blood Pressure Education Program Working Group Report on Hypertension in Diabetes: the National High Blood Pressure Education Program Working Group. Hypertension 1994; 23: 145–58.
Israili ZH, Hall WD. ACE inhibitors: differential use in elderly patients with hypertension. Drug Aging 1995; 7: 355–71.
Ravid M, Ravid D. ACE inhibitors in elderly patients with hypertension. Special considerations. Drug Aging 1996; 8: 29–37.
Matterson BJ, Reda DJ, Cushman WC, et al. for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328: 914–21.
Chrysant SG, for the Lisinopril-Hydrochlorothiazide Group. Antihypertensive effectiveness of low-dose lisinopril-hy-drochlorothiazide combination. A large multicenter study. Lisinopril-Hydrochlorothiazide Group. Arch Intern Med 1994; 154: 737–43.
Bakris GL, Weir MR, Sower JR. Therapeutic challenges in obese diabetic patients with hypertension. Am J Med 1996; 101 (Suppl. 3A): 33–46.
Guzman CB, Sower JR. Special considerations in the therapy of diabetic hypertension. Prog Cardiovasc Dis 1999; 41: 461–70.
Tatti P, Pahor M, Byington RD, et al. Outcome results of Fosinopril versus Amlodipine Cardiovascular Events randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597–603.
Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54: 1283–9.
Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT study group. Lancet 1998; 351: 1755–62.
Staessen JA, Fagard R, Thijs L, et al. for the Systolic Hypertension Europe (Syst-Eur) Trial Investigators. Morbidity and mortality in the placebo-control European trial on isolated systolic hypertension in the elderly. Lancet 1997; 350: 757–64.
Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation 1999; 100: 354–60.
Basile J. Hypertension in the elderly: A review of the importance of systolic blood pressure elevation. J Clin Hypertens 2002; 4: 108–12, 119.
Madhavan S, Ooi WL, Cohen H, et al. The relationship of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 1994; 23: 395–401.
SHEP Cooperative Research Group. Prevention of stroke and antihypertensive drug treatment in older patients with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–64.
Liu L, Wang JG, Gong L, Liu G, Staessen J, for the Systolic Hypertension in China (Syst-China) Collaborate Group. Comparison of active treatment and placebo for older patients with isolated systolic hypertension. J Hypertens 1998; 16: 1823–9.
Al-Mahroos F, McKeigue PM. High prevalence of diabetes in Bahrainis: association with ethnicity and raised plasma cholesterol. Diabetes Care 1999; 21: 936–42.
CrossRef Copyright information
© Springer Internal Publishing Switzerland 2004